Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 36.2 USD -4.16% Market Closed
Market Cap: 2B USD
Have any thoughts about
Supernus Pharmaceuticals Inc?
Write Note

Supernus Pharmaceuticals Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Supernus Pharmaceuticals Inc
Operating Income Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Operating Income
$59.3m
CAGR 3-Years
-22%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Operating Income
$24.2B
CAGR 3-Years
-1%
CAGR 5-Years
7%
CAGR 10-Years
1%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$11.1B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
13%
Pfizer Inc
NYSE:PFE
Operating Income
$13.1B
CAGR 3-Years
-17%
CAGR 5-Years
63%
CAGR 10-Years
-2%
Merck & Co Inc
NYSE:MRK
Operating Income
$21.7B
CAGR 3-Years
20%
CAGR 5-Years
10%
CAGR 10-Years
10%
Eli Lilly and Co
NYSE:LLY
Operating Income
$14.4B
CAGR 3-Years
25%
CAGR 5-Years
21%
CAGR 10-Years
15%

See Also

What is Supernus Pharmaceuticals Inc's Operating Income?
Operating Income
59.3m USD

Based on the financial report for Sep 30, 2024, Supernus Pharmaceuticals Inc's Operating Income amounts to 59.3m USD.

What is Supernus Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-17%

Over the last year, the Operating Income growth was 98%. The average annual Operating Income growth rates for Supernus Pharmaceuticals Inc have been -22% over the past three years , -17% over the past five years .

Back to Top